Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment
Authors' conclusion
For individuals with RA, making decisions about tapering bDMARDs involves considering several factors, with the most important determinants identified as dosing frequency and the risk of disease flare.
Study context
- Population
- People with rheumatoid arthritis (RA) who had experience taking a bDMARD
- Participants
- 142 complete responses
- Outcome
- Preferences for treatment-related benefits and risks of bDMARD tapering and health care service-related attributes
Methodological detailsonline, multinomial logit model
- Online
- Multinomial logit model
Main finding
As reported in the abstract
Preference weights of attributes
Reduced dosing frequency of bDMARD (largest impact on preference), mean
1.0
95% CI 0.8–1.2
Chance of disease flare, mean
0.7
95% CI 0.6–0.9
Accepted increased risk of flare in exchange for tapering benefits, lower bound
10.6%
95% CI 3.2–17.9
Accepted increased risk of flare in exchange for tapering benefits, upper bound
60.6%
95% CI 48.1–72.9
Further findings
Determinants of choice and predicted uptake
- Participants with better quality of life more likely to choose to remain on current treatment
- Predicted uptake of bDMARD tapering was high
Original publication
Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. Arthritis Care Res (Hoboken). Published 16 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →